Table 3 Adverse events and new bone fractures during treatment.
From: Denosumab versus romosozumab for postmenopausal osteoporosis treatment
Denosumab (N = 69) | Romosozumab (N = 69) | |
|---|---|---|
All adverse events | 6 (8.7) | 25 (36.2) |
Serious adverse events | ||
Breast cancer | 0 | 1 (1.4) |
Injection site reaction* | ||
Pain | 0 | 10 (14.5) |
Swelling | 0 | 4 (5.8) |
Redness | 0 | 1 (1.4) |
Itching | 0 | 2 (2.9) |
Other events of interest | ||
Anacatesthesia | 0 | 1 (1.4) |
Blindness | 1 (1.4) | 0 |
Numbness in limbs | 1 (1.4) | 0 |
Diarrhea | 1 (1.4) | 0 |
Blood pressure elevation | 0 | 1 (1.4) |
Fatigue | 0 | 1 (1.4) |
New fractures during the therapy | ||
Thoracic or lumbar spine | 2 (2.9) | 2 (2.9) |
Proximal tibial fracture | 0 | 1 (1.4) |
Rib fracture | 1 (1.4) | 0 |
Distal fibular fracture | 0 | 1 (1.4) |
